Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

March 10, 2025 World Leave a comment 0 Views

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Check Also

Lung Disease Outbreak Sparks Global Concern from NYC

Rising Concerns Over Legionnaires’ Disease Outbreaks in the U.S. Health authorities across the United States …

Leave a Reply

Your email address will not be published. Required fields are marked *